APA (7th ed.) Citation

MD, H., KJ, B., HE, J., W, M., S, E., ZJ, K., . . . SP, S. (2024). Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease. Alzheimer's research & therapy, 16(1), 154. https://doi.org/10.1186/s13195-024-01521-9

Chicago Style (17th ed.) Citation

MD, Howe, et al. "Clinical Application of Plasma P-tau217 to Assess Eligibility for Amyloid-lowering Immunotherapy in Memory Clinic Patients with Early Alzheimer's Disease." Alzheimer's Research & Therapy 16, no. 1 (2024): 154. https://doi.org/10.1186/s13195-024-01521-9.

MLA (9th ed.) Citation

MD, Howe, et al. "Clinical Application of Plasma P-tau217 to Assess Eligibility for Amyloid-lowering Immunotherapy in Memory Clinic Patients with Early Alzheimer's Disease." Alzheimer's Research & Therapy, vol. 16, no. 1, 2024, p. 154, https://doi.org/10.1186/s13195-024-01521-9.